The role of the protein MARCKS in CLL response to BTK inhibitors

Considering BTK Inhibition’s Role in Treating CLL and MCLПодробнее

The role of integrins in resistance to BTK inhibitors in CLLПодробнее

The role of next-generation BTK inhibitors in the treatment of CLLПодробнее

CLL and MCL: Factors in Selecting a BTK InhibitorПодробнее

Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients w...Подробнее

The role of PI3K inhibitors in CLLПодробнее

New Way to Block the BTK Pathway with Protein Degraders in CLL - Dr. Adrian Wiestner ASH 2022Подробнее

Evaluating the role of BTK inhibitors in CLLПодробнее

Rationale for BTK Inhibition in CLLПодробнее

Next-Generation BTK inhibitors and their role in the CLL treatment landscapeПодробнее

Combining BTK and BCL-2 inhibitors for the treatment of CLLПодробнее

Targeted Inhibition of Signal Molecules as Novel Therapy For CLLПодробнее

Prof. Jan Cools: "Oncogene cooperation in T-cell acute lymphoblastic leukemia"Подробнее

CLL: Treatment for BTKi ProgressorsПодробнее

The role of macrophage signals and CXCR4 in the growth of CLL cellsПодробнее

Current state of the field: non-covalent BTK inhibitors for CLLПодробнее

CLL: BTK Inhibitors in Hematologic Oncology Pathways - Pathway-Guided ChoicesПодробнее

Overview of Bruton's tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemiaПодробнее